Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

NANot yet recruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Ischemic StrokeTransient Ischemic Attack (TIA)
Interventions
DEVICE

the Intelligent Lipid Management Decision-support System

Doctor's Side: Long-term lipid management support based on guidelines/consensus• Provides lipid management pathways based on guidelines/consensus to ensure clinical decisions align with the latest standards.• Combines individualized patient data to offer intelligent lipid management and medication suggestions.• Provides medical education support to enhance doctors' awareness of guidelines, consensus, and management strategies.Patient's Side: Personalized lipid risk assessment and regular reminders• Based on the lipid test reports uploaded by patients via photos, provides lipid test reports tailored to the patient's risk stratification.• Uses digital tools to regularly remind patients, optimizing follow-up adherence and medication compliance.

Trial Locations (1)

Unknown

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT07143149 - Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China | Biotech Hunter | Biotech Hunter